The Vanguard Group 13D and 13G filings for NovoCure Limited:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-07-10 1:14 pm Purchase | 2024-06-28 | 13G | NovoCure Limited NVCR | The Vanguard Group | 11,127,354 10.340% | 1,368,267 (+14.02%) | Filing |
| 2024-02-13 5:09 pm Purchase | 2023-12-29 | 13G | NovoCure Limited NVCR | The Vanguard Group | 9,759,087 9.130% | 211,751 (+2.22%) | Filing |
| 2023-02-09 11:27 am Purchase | 2022-12-30 | 13G | NovoCure Limited NVCR | The Vanguard Group | 9,547,336 9.100% | 1,654,023 (+20.95%) | Filing |
| 2022-02-10 08:27 am Sale | 2021-12-31 | 13G | NovoCure Limited NVCR | The Vanguard Group | 7,893,313 7.600% | -350,657 (-4.25%) | Filing |
| 2021-02-10 11:40 am Purchase | 2020-12-31 | 13G | NovoCure Limited NVCR | The Vanguard Group | 8,243,970 8.100% | 990,600 (+13.66%) | Filing |